MEMBER LOGIN: Your Email: Password: Remember Me
Forgot Your Password or would like to register?
JNJ Johnson & Johnson
As Of 11/13/2018 7:11:00 PM
Current Price$144.68
Current Rating1
Return Since 12/2015
Johnson & Johnson 51.88 %
S&P 50030.37 %
VFS Rating Analysis
Market ReturnAverage
return vs market
Related Links
Company News
Earnings Call Transcripts
Options Chain
Options Pricing History
For current estimates, historical performance information and more, Log in to your account.

Monthly Performance and Prediction History
Below is the monthly performance history for this security and the monthly change as compared to the stock market for this security. When a row is highlighted in green, it is identifying a stock that the model predict will outperform the portfolio for that month. When a row is highlighted in red, it is identifying a stock that the model predicted will underperform for the month. No highlight indicates the model is neutral on the stock. These predictions are always recorded at the beginning of the month, and table below shows the resulting return for the month.
DateVFS RatingPredictionRating PriceSubsequent
% Increase
Market %
Increase *
11-01-20181 $139.99   
10-01-20181 $138.171.32%-6.91%8.23%
8-01-20182 $132.522.32%3.19%-0.88%
5-01-20183 $126.49-4.72%2.43%-7.15%
4-01-20182 $128.15-1.30%0.52%-1.81%
3-01-20182 $129.88-1.33%-3.13%1.80%
* As measured by the performance of the S&P 500 for the month.

JNJ, SYK14Understanding TransEnterix’s Operational Performance ( 9:23:00 AM
JNJ14See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ14Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know ( 2:45:00 PM
JNJ14Johnson & Johnson to Participate in the Citi's 2018 Global Healthcare Conference ( 5:00:00 AM
JNJ14Hedge Fund Sentiment is Turning Against Johnson & Johnson (JNJ) ( 11:23:00 AM
JNJ14See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ14A Look at Alexion Pharmaceuticals’ Operational Performance ( 10:35:00 AM
JNJ14Merck and Johnson & Johnson Shares Show Big Buying ( 5:42:00 AM
JNJ13Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know ( 2:45:00 PM
JNJ13Johnson & Johnson to Participate in the Credit Suisse 27th Annual Healthcare Conference ( 7:09:00 AM
JNJ13Jim Cramer: The Stock Market's Machine Buyers ( 8:17:00 AM
JNJ13See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:02:00 AM
JNJ9Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic ( 10:30:00 PM
JNJ9The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Lockheed Martin and Boeing ( 6:24:00 AM
JNJ8Johnson & Johnson Vision Announces Health Canada has issued a Medical Device License for First-of-its-Kind Contact Lens ACUVUE OASYS with Transitions Light Intelligent Technology ( 9:36:00 AM
JNJ8The Zacks Analyst Blog Highlights: HCA Healthcare, Molina Healthcare, Johnson & Johnson, Facebook and Twitter ( 5:31:00 AM
JNJ8The Zacks Analyst Blog Highlights: Intel, Exxon Mobil, Johnson & Johnson, JPMorgan and Microsoft ( 4:40:00 AM
JNJ43 Top Healthcare Stocks to Buy in November ( 5:01:00 PM
JNJ, SYK4How TransEnterix Has Been Performing in November ( 9:23:00 AM
JNJ4Stock Market Power Rankings: Last Call for Facebook ( 8:11:00 AM
JNJ4Here’s how to easily reduce your investment risk just at the right time ( 6:54:00 AM
JNJ47 Dividend Stocks With Rising Payouts ( 7:55:00 AM
JNJ4How Analysts View Alexion Stock ( 7:31:00 AM
JNJ4Analyzing Alexion Pharmaceuticals’ Dicerna Collaboration ( 6:01:00 AM
JNJ4Healthcare ETF (JHMH) Hits New 52-Week High ( 4:13:00 PM
JNJ4Analyzing Alexion Pharmaceuticals’ Product Performance ( 10:35:00 AM
JNJ4How Alexion Is Positioned in November ( 10:35:00 AM
JNJ4Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ ( 7:58:00 AM
JNJ4Democrats Hold Edge in House Battle: 5 Great Picks (Revised) ( 5:14:00 AM
NKE, JNJ35 Dow Stocks to Sell (And 2 to Buy) ( 7:39:00 AM
JNJ3Cramer on Washington gridlock: Buy fast growers ( 3:43:00 PM
JNJ3Cramer's advice on investing during Washington gridlock: ... ( 3:39:00 PM
JNJ3Better Buy: Eli Lilly and Company vs. AbbVie Inc. ( 1:53:00 PM
JNJ3Dow, Nasdaq Rally Strong As Growth Stocks Show These 5 Bullish Signs ( 12:30:00 PM
JNJ3'We have a lot of things in common' — Trump wants to work with Democrats on infrastructure, drugs ( 9:16:00 AM
JNJ3Here's Why Arrowhead Pharmaceuticals Dropped 33.6% in October ( 8:23:00 AM
JNJ35 Top Stocks to Make the Most of a Divided Congress ( 4:29:00 AM
JNJ3Beaten-Down Pharma ETFs to Buy Post Q3 Results ( 8:20:00 AM
JNJ3Two Studies Measure Performance of ACUVUE OASYS with Transitions Light Intelligent Technology Contact Lenses in Simulated Sunlight, Day and Night Driving Conditions ( 6:19:00 AM
JNJ3Democrats Hold Edge in House Battle: 5 Great Picks ( 4:00:00 AM
JNJ3Gilead Sciences: Analysts’ Recommendations ( 6:00:00 AM
JNJ3AbbVie sees hit to Humira sales from European competition ( 11:24:00 AM
JNJ3MARKETS: Now Facebook, J&J, Pfizer and Merck are dragging down the market, while Exxon and Chevron are bright spots ( 10:23:00 AM
JNJ3AbbVie Earnings, Revenue beat in Q3 ( 7:50:00 AM
JNJ3How Geron's Horrible Year Is a Great Reminder to Investors ( 7:43:00 AM
JNJ35 of the Best Blue-Chip Stocks to Ride the Dow Rally ( 7:42:00 AM
JNJ3Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down ( 6:15:00 AM
JNJ3Scary Markets, Frightening Stocks, and How to Keep From Panicking ( 5:21:00 PM
JNJ3Why Geron Corporation Stock Is Ripping Higher Today ( 11:55:00 AM
JNJ3Baxter Earnings beat, Revenue misses In Q3 ( 3:28:00 PM
JNJ3J&J CEO Must Face Questioning Over Baby Powder Statements ( 2:26:00 PM
JNJ2Zoetis Inc Earnings, Revenue beat in Q3 ( 7:08:00 AM
JNJ2The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead ( 11:52:00 AM
JNJ23 Charts That Suggest It's Time to Buy Healthcare Stocks ( 10:04:00 AM
JNJ2Merck’s Gardasil Had Solid Growth in the Third Quarter ( 9:35:00 AM
JNJ2How Merck Stands Financially in October ( 8:05:00 AM
JNJ2Gauging Analysts’ Views on Bristol-Myers Squibb Stock ( 7:30:00 AM

WEBSITE DISCLAIMER:  Puget Investors and Vertical Financial Systems, Inc are not registered investment advisers, broker/dealers, or research analysts/organizations. The content on this website is issued solely for information purposes and should not to be construed as an offer to buy, sell, or trade in any way, any security mentioned herein.

All information presented on this website is believed to be reliable and written in good faith, but no representation or warranty, expressed or implied is made as to their accuracy, completeness or correctness. You are responsible for doing your own research before investing in any securities mentioned herein. Readers are urged to consult with their own independent financial advisors with respect to any investment. Neither Vertical Financial Systems, Inc, nor its officers or employees accept any liability whatsoever for any direct or consequential loss arising from any use of information on this website.

Past performance is not a guarantee of future performance or accuracy. Rating calculations and methodology may change at any time, and we reserve the right to make changes which may impact the accuracy of the model without prior notice to anybody.

Be advised that employees and officers of Vertical Financial Systems, Inc and may hold positions in the securities mentioned in this website.
Website Operated by Vertical Financial Systems, Inc